Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through interactions with SLC2A1

Heaton, Bethany J ORCID: 0000-0002-1495-1945, Jensen, Rebecca L ORCID: 0000-0003-1134-2869, Line, James ORCID: 0000-0003-3568-8928, David, Christopher AW ORCID: 0000-0001-8504-2354, Brain, Danielle E ORCID: 0000-0002-1671-8477, Chadwick, Amy E ORCID: 0000-0002-7399-8655 and Liptrott, Neill J ORCID: 0000-0002-5980-8966 (2022) Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through interactions with SLC2A1. BIOMEDICINE & PHARMACOTHERAPY, 150. 112999-.

Text Revised_GLUTs and ARVs_BJH_NJL_CAWD_RLJ_DEB_AEC_JLi.docx - Author Accepted Manuscript Download (6MB)

Abstract

SLC2A1 mediates glucose cellular uptake; key to appropriate immune function. Our previous work has shown efavirenz and lopinavir exposure inhibits T cell and macrophage responses, to known agonists, likely via interactions with glucose transporters. Using human cell lines as a model, we assessed glucose uptake and subsequent bioenergetic profiles, linked to immunological responses. Glucose uptake was measured using 2-deoxyglucose as a surrogate for endogenous glucose, using commercially available reagents. mRNA expression of SLC transporters was investigated using qPCR TaqMan™ gene expression assay. Bioenergetic assessment, on THP-1 cells, utilised the Agilent Seahorse XF Mito Stress test. In silico analysis of potential interactions between SLC2A1 and antiretrovirals was investigated using bioinformatic techniques. Efavirenz and lopinavir exposure was associated with significantly lower glucose accumulation, most notably in THP-1 cells (up to 90% lower and 70% lower with efavirenz and lopinavir, respectively). Bioenergetic assessment showed differences in the rate of ATP production (J_ATP); efavirenz (4 μg/mL), was shown to reduce J_ATP by 87% whereas lopinavir (10 μg/mL), was shown to increase the overall J_ATP by 77%. Putative in silico analysis indicated the antiretrovirals, apart from efavirenz, associated with the binding site of highest binding affinity to SLC2A1, similar to that of glucose. Our data suggest a role for efavirenz and lopinavir in the alteration of glucose accumulation with subsequent alteration of bioenergetic profiles, supporting our hypothesis for their inhibitory effect on immune cell activation. Clarification of the implications of this data, for in vivo immunological responses, is now warranted to define possible consequences for these, and similar, therapeutics.

Item Type:	Article
Uncontrolled Keywords:	Antiretroviral, Immune response, HIV, Membrane transporter, Glucose, Bioenergetics
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User:	Symplectic Admin
Date Deposited:	19 Apr 2022 15:06
Last Modified:	18 Jan 2023 21:05
DOI:	10.1016/j.biopha.2022.112999
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3153363